Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF‐1 upregulation of TUBB2B beta‐tubulin isoform. Issue 7 (18th March 2021)

• Record Type: Journal Article
• Authors: Liotti, Antonietta; La Civita, Evelina; Cennamo, Michele; Crocetto, Felice; Ferro, Matteo; Guadagno, Elia; Insabato, Luigi; Imbimbo, Ciro; Palmieri, Alessandro; Mirone, Vincenzo; Liguoro, Pasquale; Formisano, Pietro; Beguinot, Francesco; Terracciano, Daniela
• Is Part Of: Prostate. Volume 81:Issue 7(2021)
• Page Start: 407
• Page End: 417
• Publication Date: 2021-03-18
• Subjects: adipocytes -- docetaxel -- drug resistance -- periprostatic adipose tissue -- prostate cancer; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.24117
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract: Growing evidence supports the pivotal role played by periprostatic adipose tissue (PPAT) in prostate cancer (PCa) microenvironment. We investigated whether PPAT can affect response to Docetaxel (DCTX) and the mechanisms associated. Conditioned medium was collected from the in vitro differentiated adipocytes isolated from PPAT which was isolated from PCa patients, during radical prostatectomy. Drug efficacy was studied by 3‐(4, 5‐dimethylthiazol‐2‐yl)‐2, 5‐diphenyltetrazolium bromide citotoxicity assay. Culture with CM of human PPAT (AdipoCM) promotes DCTX resistance in two different human prostate cancer cell lines (DU145 and PC3) and upregulated the expression of BCL‐xL, BCL‐2, and TUBB2B. AG1024, a well‐known IGF‐1 receptor inhibitor, counteracts the decreased response to DCTX observed in presence of AdipoCM and decreased TUBB2B expression, suggesting that a paracrine secretion of IGF‐1 by PPAT affect DCTX response of PCa cell. Collectively, our study showed that factors secreted by PPAT elicits DCTX resistance through antiapoptotic proteins and TUBB2B upregulation in androgen independent PCa cell lines. These findings reveal the potential of novel therapeutic strategies targeting adipocyte‐released factors and IGF‐1 axis to overcome DCTX resistance in patients with PCa.